Literature DB >> 19884385

Opposite clinical phenotypes of glucokinase disease: Description of a novel activating mutation and contiguous inactivating mutations in human glucokinase (GCK) gene.

Fabrizio Barbetti1, Nadia Cobo-Vuilleumier, Carlo Dionisi-Vici, Sonia Toni, Paolo Ciampalini, Ornella Massa, Pablo Rodriguez-Bada, Carlo Colombo, Lorenzo Lenzi, María A Garcia-Gimeno, Francisco J Bermudez-Silva, Fernando Rodriguez de Fonseca, Patrizia Banin, Juan C Aledo, Elena Baixeras, Pascual Sanz, Antonio L Cuesta-Muñoz.   

Abstract

Glucokinase is essential for glucose-stimulated insulin release from the pancreatic beta-cell, serving as glucose sensor in humans. Inactivating or activating mutations of glucokinase lead to different forms of glucokinase disease, i.e. GCK-monogenic diabetes of youth, permanent neonatal diabetes (inactivating mutations), and congenital hyperinsulinism, respectively. Here we present a novel glucokinase gene (GCK)-activating mutation (p.E442K) found in an infant with neonatal hypoglycemia (1.5 mmol/liter) and in two other family members suffering from recurrent hypoglycemic episodes in their childhood and adult life. In contrast to the severe clinical presentation in the index case, functional studies showed only a slight activation of the protein (relative activity index of 3.3). We also report on functional studies of two inactivating mutations of the GCK (p.E440G and p.S441W), contiguous to the activating one, that lead to monogenic diabetes of youth. Interestingly, adult family members carrying the GCK pE440G mutation show an unusually heterogeneous and progressive diabetic phenotype, a feature not typical of GCK-monogenic diabetes of youth. In summary, we identified a novel activating GCK mutation that although being associated with severe neonatal hypoglycemia is characterized by the mildest activation of the glucokinase enzyme of all previously reported.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19884385      PMCID: PMC5419125          DOI: 10.1210/me.2009-0094

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  21 in total

1.  Normal values of first-phase insulin response to intravenous glucose in healthy Italian children and adolescents.

Authors:  R Lorini; M Vanelli
Journal:  Diabetologia       Date:  1996-03       Impact factor: 10.122

2.  Mutants of glucokinase cause hypoglycaemia- and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasis.

Authors:  E A Davis; A Cuesta-Muñoz; M Raoul; C Buettger; I Sweet; M Moates; M A Magnuson; F M Matschinsky
Journal:  Diabetologia       Date:  1999-10       Impact factor: 10.122

Review 3.  Glucokinase (GCK) mutations in hyper- and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy.

Authors:  Anna L Gloyn
Journal:  Hum Mutat       Date:  2003-11       Impact factor: 4.878

4.  Activating glucokinase (GCK) mutations as a cause of medically responsive congenital hyperinsulinism: prevalence in children and characterisation of a novel GCK mutation.

Authors:  Henrik B T Christesen; Nicholas D Tribble; Anders Molven; Juveria Siddiqui; Tone Sandal; Klaus Brusgaard; Sian Ellard; Pål R Njølstad; Jan Alm; Bendt Brock Jacobsen; Khalid Hussain; Anna L Gloyn
Journal:  Eur J Endocrinol       Date:  2008-05-01       Impact factor: 6.664

Review 5.  Hyperinsulinism/hyperammonemia syndrome: insights into the regulatory role of glutamate dehydrogenase in ammonia metabolism.

Authors:  Charles A Stanley
Journal:  Mol Genet Metab       Date:  2004-04       Impact factor: 4.797

6.  Permanent neonatal diabetes caused by glucokinase deficiency: inborn error of the glucose-insulin signaling pathway.

Authors:  Pål R Njølstad; Jørn V Sagen; Lise Bjørkhaug; Stella Odili; Naim Shehadeh; Doua Bakry; S Umit Sarici; Faruk Alpay; Janne Molnes; Anders Molven; Oddmund Søvik; Franz M Matschinsky
Journal:  Diabetes       Date:  2003-11       Impact factor: 9.461

Review 7.  Assessing the potential of glucokinase activators in diabetes therapy.

Authors:  Franz M Matschinsky
Journal:  Nat Rev Drug Discov       Date:  2009-04-17       Impact factor: 84.694

8.  Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase.

Authors:  Kenji Kamata; Morihiro Mitsuya; Teruyuki Nishimura; Jun-Ichi Eiki; Yasufumi Nagata
Journal:  Structure       Date:  2004-03       Impact factor: 5.006

9.  Neonatal diabetes mellitus due to complete glucokinase deficiency.

Authors:  P R Njølstad; O Søvik; A Cuesta-Muñoz; L Bjørkhaug; O Massa; F Barbetti; D E Undlien; C Shiota; M A Magnuson; A Molven; F M Matschinsky; G I Bell
Journal:  N Engl J Med       Date:  2001-05-24       Impact factor: 91.245

10.  The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy.

Authors:  Henrik B T Christesen; Bendt B Jacobsen; Stella Odili; Carol Buettger; Antonio Cuesta-Munoz; Torben Hansen; Klaus Brusgaard; Ornella Massa; Mark A Magnuson; Chiyo Shiota; Franz M Matschinsky; Fabrizio Barbetti
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

View more
  14 in total

1.  Lack of glibenclamide response in a case of permanent neonatal diabetes caused by incomplete inactivation of glucokinase.

Authors:  Josep Oriola; Francisca Moreno; Angel Gutiérrez-Nogués; Sara León; Carmen-María García-Herrero; Olivier Vincent; María-Angeles Navas
Journal:  JIMD Rep       Date:  2015-02-10

Review 2.  Mutations in pancreatic ß-cell Glucokinase as a cause of hyperinsulinaemic hypoglycaemia and neonatal diabetes mellitus.

Authors:  Khalid Hussain
Journal:  Rev Endocr Metab Disord       Date:  2010-09       Impact factor: 6.514

Review 3.  Current understanding of K ATP channels in neonatal diseases: focus on insulin secretion disorders.

Authors:  Yi Quan; Andrew Barszczyk; Zhong-ping Feng; Hong-shuo Sun
Journal:  Acta Pharmacol Sin       Date:  2011-05-23       Impact factor: 6.150

4.  A phospho-BAD BH3 helix activates glucokinase by a mechanism distinct from that of allosteric activators.

Authors:  Benjamin Szlyk; Craig R Braun; Sanda Ljubicic; Elaura Patton; Gregory H Bird; Mayowa A Osundiji; Franz M Matschinsky; Loren D Walensky; Nika N Danial
Journal:  Nat Struct Mol Biol       Date:  2013-12-08       Impact factor: 15.369

5.  Discovery of a novel site regulating glucokinase activity following characterization of a new mutation causing hyperinsulinemic hypoglycemia in humans.

Authors:  Nicola L Beer; Martijn van de Bunt; Kevin Colclough; Christine Lukacs; Paul Arundel; Constance L Chik; Joseph Grimsby; Sian Ellard; Anna L Gloyn
Journal:  J Biol Chem       Date:  2011-03-29       Impact factor: 5.157

6.  How Heterogeneity in Glucokinase and Gap-Junction Coupling Determines the Islet [Ca2+] Response.

Authors:  JaeAnn M Dwulet; Nurin W F Ludin; Robert A Piscopio; Wolfgang E Schleicher; Ong Moua; Matthew J Westacott; Richard K P Benninger
Journal:  Biophys J       Date:  2019-11-05       Impact factor: 4.033

7.  Glucokinase mutation-a rare cause of recurrent hypoglycemia in adults: a case report and literature review.

Authors:  Oluremi N Ajala; David M Huffman; Ibrahim I Ghobrial
Journal:  J Community Hosp Intern Med Perspect       Date:  2016-10-26

Review 8.  Congenital Hyperinsulinism: Diagnosis and Treatment Update.

Authors:  Hüseyin Demirbilek; Khalid Hussain
Journal:  J Clin Res Pediatr Endocrinol       Date:  2017-12-27

Review 9.  Normal glucose metabolism in carnivores overlaps with diabetes pathology in non-carnivores.

Authors:  Thomas Schermerhorn
Journal:  Front Endocrinol (Lausanne)       Date:  2013-12-03       Impact factor: 5.555

Review 10.  Congenital hyperinsulinism: current status and future perspectives.

Authors:  Tohru Yorifuji
Journal:  Ann Pediatr Endocrinol Metab       Date:  2014-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.